Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma.

Tong AA, Hashem H, Eid S, Allen F, Kingsley D, Huang AY.

Oncoimmunology. 2017 Mar 16;6(4):e1303586. doi: 10.1080/2162402X.2017.1303586. eCollection 2017.

2.

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C.

Oncoimmunology. 2016 Oct 28;6(1):e1250050. doi: 10.1080/2162402X.2016.1250050. eCollection 2017.

3.

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.

Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, Dranoff G, Fanger MW, Sentman CL.

J Immunol. 2016 Dec 15;197(12):4674-4685. Epub 2016 Nov 14.

PMID:
27849169
4.

Potential approaches to the treatment of Ewing's sarcoma.

Yu H, Ge Y, Guo L, Huang L.

Oncotarget. 2017 Jan 17;8(3):5523-5539. doi: 10.18632/oncotarget.12566. Review.

5.

IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing.

Braun M, Ress ML, Yoo YE, Scholz CJ, Eyrich M, Schlegel PG, Wölfl M.

Oncoimmunology. 2016 May 19;5(7):e1188245. doi: 10.1080/2162402X.2016.1188245. eCollection 2016 Jul.

6.

Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.

Bücklein V, Adunka T, Mendler AN, Issels R, Subklewe M, Schmollinger JC, Noessner E.

Oncoimmunology. 2016 Apr 29;5(7):e1178421. doi: 10.1080/2162402X.2016.1178421. eCollection 2016 Jul.

7.

Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.

Sand LG, Berghuis D, Szuhai K, Hogendoorn PC.

Cancer Immunol Immunother. 2016 Aug;65(8):995-1002. doi: 10.1007/s00262-016-1862-1. Epub 2016 Jul 1.

8.

Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.

Fisher JP, Flutter B, Wesemann F, Frosch J, Rossig C, Gustafsson K, Anderson J.

Oncoimmunology. 2015 Apr 27;5(1):e1025194. eCollection 2016.

9.

Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.

Huang MA, Krishnadas DK, Lucas KG.

J Immunol Res. 2015;2015:675269. doi: 10.1155/2015/675269. Epub 2015 Oct 26. Review.

10.

Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells.

Reuter D, Staege MS, Kühnöl CD, Föll J.

Front Oncol. 2015 Oct 27;5:242. doi: 10.3389/fonc.2015.00242. eCollection 2015.

11.

DNAM-1 controls NK cell activation via an ITT-like motif.

Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A.

J Exp Med. 2015 Nov 16;212(12):2165-82. doi: 10.1084/jem.20150792. Epub 2015 Nov 9.

12.

CD226 gene polymorphisms are associated with non-small-cell lung cancer in the Chinese Han population.

Qiu ZX, Peng Y, Li WM.

Ther Clin Risk Manag. 2015 Aug 24;11:1259-64. doi: 10.2147/TCRM.S90365. eCollection 2015.

13.

Immunotherapy of Childhood Sarcomas.

Roberts SS, Chou AJ, Cheung NK.

Front Oncol. 2015 Aug 7;5:181. doi: 10.3389/fonc.2015.00181. eCollection 2015. Review.

14.

The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas.

Liang S, Yang Z, Li D, Miao X, Yang L, Zou Q, Yuan Y.

Dis Markers. 2015;2015:379568. doi: 10.1155/2015/379568. Epub 2015 Jul 30.

15.

Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.

Xiong P, Sang HW, Zhu M.

Immunology. 2015 Nov;146(3):369-78. doi: 10.1111/imm.12516. Epub 2015 Sep 28. Review.

16.

Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes.

Sand LG, Szuhai K, Hogendoorn PC.

Int J Mol Sci. 2015 Jul 16;16(7):16176-215. doi: 10.3390/ijms160716176. Review.

17.

Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.

Boerman GH, van Ostaijen-ten Dam MM, Kraal KC, Santos SJ, Ball LM, Lankester AC, Schilham MW, Egeler RM, van Tol MJ.

Cancer Immunol Immunother. 2015 May;64(5):573-83. doi: 10.1007/s00262-015-1657-9. Epub 2015 Feb 18.

18.

Adoptive cell therapy for sarcoma.

Mata M, Gottschalk S.

Immunotherapy. 2015;7(1):21-35. doi: 10.2217/imt.14.98. Review.

19.

DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.

Wu MR, Zhang T, Alcon A, Sentman CL.

Cancer Immunol Immunother. 2015 Apr;64(4):409-18. doi: 10.1007/s00262-014-1648-2. Epub 2014 Dec 31.

20.

Immunotherapy in pediatric malignancies: current status and future perspectives.

Capitini CM, Otto M, DeSantes KB, Sondel PM.

Future Oncol. 2014;10(9):1659-78. doi: 10.2217/fon.14.62. Review.

Supplemental Content

Support Center